{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:16Z","timestamp":1791489616430,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":235,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101412","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:46:55Z","timestamp":1788252415000},"page":"101412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world treatment persistence of first-line atezolizumab in elderly patients with PD-L1\u2013high NSCLC: comparison with pembrolizumab"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1500-5215","authenticated-orcid":false,"given":"Tomohiro","family":"Oba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9935-6653","authenticated-orcid":false,"given":"Keiichi","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ctarc.2026.101412_bib0001","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101412_bib0002","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic NSCLC with PD-L1 TPS \u226550%","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101412_bib0003","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected non\u2013small-cell lung cancer","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101412_bib0004","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive PD-L1\u2013selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101412_bib0005","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1200\/JCO-25-01062","article-title":"Therapy for stage IV non\u2013small cell lung cancer without driver alterations: ASCO living guideline, version 2025.1","volume":"43","author":"Owen","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101412_bib0006","first-page":"1123","article-title":"Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non\u2013small cell lung cancer","volume":"31","author":"Xue","year":"2025","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101412_bib0007","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2009.03.001","article-title":"A most stubborn bias: confounding by indication in observational studies","volume":"63","author":"Bosco","year":"2010","journal-title":"J. Clin. Epidemiol."},{"issue":"10400","key":"10.1016\/j.ctarc.2026.101412_bib0008","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(23)00774-2","article-title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non\u2013small-cell lung cancer ineligible for platinum-containing regimens (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study","volume":"402","author":"Lee","year":"2023","journal-title":"Lancet"},{"issue":"9596","key":"10.1016\/j.ctarc.2026.101412_bib0009","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101412_bib0010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non\u2013small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101412_bib0011","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","article-title":"Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis","volume":"4","author":"Ritchie","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101412_bib0012","doi-asserted-by":"crossref","unstructured":"Gajra A, Zemla TJ, Jatoi A, et al. Time-to-treatment-failure and related outcomes among 1000 patients with advanced non\u2013small cell lung cancer: comparisons between older versus younger patients (Alliance A151711). J. Thorac. Oncol.. 2018;13(7):996\u20131003. doi:10.1016\/j.jtho.2018.03.020.","DOI":"10.1016\/j.jtho.2018.03.020"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101412_bib0013","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101412_bib0014","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s12325-019-00970-1","article-title":"Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non\u2013small cell lung cancer","volume":"36","author":"Griffith","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ctarc.2026.101412_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00013","article-title":"Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non\u2013small-cell lung cancer data set","volume":"3","author":"Griffith","year":"2019","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.ctarc.2026.101412_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103081","article-title":"Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non\u2013small cell lung cancer: a systematic review and meta-analysis","volume":"81","author":"Yao","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101412_bib0017","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.21037\/tlcr-21-15","article-title":"First-line immunotherapy in non\u2013small cell lung cancer patients with poor performance status: a systematic review and meta-analysis","volume":"10","author":"Facchinetti","year":"2021","journal-title":"Transl. Lung Cancer Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:38:22Z","timestamp":1791488302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":17,"alternative-id":["S2468294226003229"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101412","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment persistence of first-line atezolizumab in elderly patients with PD-L1\u2013high NSCLC: comparison with pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101412"}}